- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly's Alzheimer's finding triggers investor hope, doctor caution
August 27, 2012
Bloomberg NewsWhile investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression
early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
MoreLilly wins appeal upholding patent for Alimta cancer drug
August 24, 2012
Bloomberg NewsEli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and
blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
MoreAlzheimer's drug results leave Lilly 'excited' but uncertain
August 24, 2012
J.K. WallThe surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly
and Co., but it raised as many questions as it answered.
MoreLilly's Alzheimer's drug trials show mixed results
August 24, 2012
Bloomberg News, J.K. WallEli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials.
However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some
patients.
MoreAlzheimer's quest puts Lilly to test
August 11, 2012
J.K. WallOdds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results
are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a
home run for Lilly.
MoreLilly to book $790M Amylin payment in third quarter
August 9, 2012
Associated PressEli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former
drug development partner Amylin Pharmaceuticals.
MoreLilly stock slips after competitors halt Alzheimer's plans
August 7, 2012
IBJ Staff and Bloomberg NewsPfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second
trial failure. Eli Lilly is developing a similar treatment.
MoreLilly braces for decline in Europe
July 30, 2012
J.K. WallAusterity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company
is moving forward with plans to survive a coming swoon anyway.
MoreLilly's quarterly profit falls, but tops analyst expectations
July 25, 2012
Bloomberg NewsEli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook
for the rest of the year.
MorePotential Alzheimer’s drug fails first of four key trials
July 24, 2012
Bloomberg NewsBapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to
target a cause for Alzheimer’s, rather than just its symptoms.
MorePotential Lilly antipsychotic falls short in study
July 11, 2012
Associated PressEli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking
the drug to those taking a placebo.
MoreCompeting Alzheimer's treatments facing long odds
July 11, 2012
Bloomberg NewsJohnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available
drug designed to target a cause of Alzheimer's, rather than just its symptoms. Analysts say the potential drugs are long shots.
MoreLilly gets 6-month Cymbalta marketing extension
July 6, 2012
Associated PressEli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta,
its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
MoreLilly cancer treatment fails trial in stomach cancer
July 5, 2012
IBJ Staff and Bloomberg NewsErbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with
advanced stomach tumors in a late-stage clinical trial.
MoreBristol-Myers to buy former Lilly partner Amylin for $5.3B
June 30, 2012
Bloomberg NewsBristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals
Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment
to Eli Lilly and Co. of about $1.7 billion.
MoreLife sciences hold up in recession
June 25, 2012
J.K. WallA new report shows Indiana’s life sciences companies performed better than their peers around the country—and
far better than the rest of Indiana’s private sector—during the early phases of the economic downturn.
MoreJ&J, Bayer fail to win U.S. OK for expanded Xarelto use
June 22, 2012
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta
from London-based AstraZeneca Plc.
MoreLilly resumes $3B stock buyback program, declares dividend
June 19, 2012
Associated PressThe local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the
end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
MoreLargest Indiana public companies mostly fared well in 2011
June 16, 2012
Performance varied widely as industries ebbed, flowed.
MoreWeb domain requests include .Cialis, .Walmart
June 14, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and other corporate heavyweights are applying for Web suffixes including .cialis, .walmart
and .jpmorgan under a program to expand the number of Internet domain names beyond .com.
MoreLilly sinks $20M into Chinese firm for 'branded generic' drugs
June 12, 2012
J.K. WallEli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio
of branded generic medicines in the fast-growing Asian market.
MoreLilly chases Novo in insulin race
June 11, 2012
J.K. WallEli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference
in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
MoreGood cholesterol may not lower heart risk, study suggests
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
MoreU.S. losing drug-research jobs to other countries
May 17, 2012
Bloomberg NewsEli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore,
Ireland and South Africa boost incentives.
MoreLilly unlikely to gain from Plavix patent loss, analyst says
May 17, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more
of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection
Thursday.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.